Incannex Healthcare Inc. (IXHL) Fair Value 2026

IXHL · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-28, Incannex Healthcare Inc. (IXHL) trades at $3.64. QOC: 5.1/10. Value Trap Risk: 34/100 (LOW). 1/13 models active.

Key Facts

Ticker
IXHL
Price
$3.64
Quality Score
5.1/10
Value Trap Risk
34/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give IXHL?

1 Intrinsic Value Models vs. Current Price ($3.64)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $2.11 -42.0%

All Models Active

All 1 models are displayed above.

What Is Incannex Healthcare Inc. (IXHL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Incannex Healthcare Inc.'s intrinsic value is estimated at $2.11, suggesting the stock is overvalued at its current price of $3.64. With 1 out of 1 models flagging downside (-42.0% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About IXHL?

1 of 13 models are currently active for IXHL. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does IXHL Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, IXHL ranks #78 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a pharmaceutical industry, Incannex Healthcare Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating IXHL should weigh these sector-specific dynamics alongside our model-derived fair values.

Is IXHL a Value Trap?

CirclFi's Value Trap algorithm assigns IXHL a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Incannex Healthcare Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Incannex Healthcare Inc.'s fundamental quality profile registers 5.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IXHL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IXHL's 1 active models, average confidence is 48%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Incannex Healthcare Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

NTRRNeutra Corp.QOC 5.1CANNTrees CorporationQOC 5.1AMLXAmylyx Pharmaceuticals, Inc.QOC 5.1APUSApimeds Pharmaceuticals US, Inc.QOC 5.0IMCCIM Cannabis Corp.QOC 5.2HYEXHealthy Extracts Inc.QOC 4.9GCANTrafalgar International, Inc.QOC 3.1PCRXPacira BioSciences, Inc.QOC 7.8SCYXSCYNEXIS, Inc.QOC 6.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: NTRR · CANN · AMLX · APUS · IMCC · HYEX · GCAN · PCRX · SCYX · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to IXHL?

7 companies across all industries closest to IXHL’s Quality of Company score of 5.1/10.

GDTCCytoMed Therapeutics LimitedQOC 5.1MCRBSeres Therapeutics, Inc.QOC 5.1LGVNLongeveron Inc.QOC 5.1CELUCelularity Inc.QOC 5.1IVFINVO Fertility, Inc.QOC 5.1FCUVFocus Universal Inc.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GDTC · MCRB · LGVN · CELU · IVF · FCUV · NVDA

Where Does IXHL Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

IXHL is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Incannex Healthcare Inc.’s Valuation?

What is Incannex Healthcare Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Incannex Healthcare Inc. (IXHL). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IXHL overvalued or undervalued right now?

At $3.64, 0 of 1 active models suggest IXHL may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Incannex Healthcare Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.1 mean for IXHL?

Incannex Healthcare Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IXHL?

CirclFi analyzes IXHL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is IXHL a value trap in 2026?

Incannex Healthcare Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Incannex Healthcare Inc. (IXHL) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/IXHL/ · Methodology
Primary sources for this IXHL valuation
  • Financial statements: Incannex Healthcare Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001873875) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for IXHL as of ; valuations recomputed .